IL17A and irritable bowel syndrome: Drugs targeting other pathways, such as anti-IL-23/IL-17 therapy and antiadhesion therapy, and small molecule inhibitors, like JAK inhibitors or S1P receptor modulators, appear promising for the management of IBD [7].